Zevra Therapeutics (ZVRA) EBT Margin (2016 - 2025)
Historic EBT Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 3.74%.
- Zevra Therapeutics' EBT Margin rose 8942300.0% to 3.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.55%, marking a year-over-year increase of 4296100.0%. This contributed to the annual value of 381.76% for FY2024, which is 2140700.0% down from last year.
- According to the latest figures from Q3 2025, Zevra Therapeutics' EBT Margin is 3.74%, which was up 8942300.0% from 296.93% recorded in Q2 2025.
- Zevra Therapeutics' 5-year EBT Margin high stood at 319.93% for Q4 2022, and its period low was 1904.38% during Q2 2022.
- Over the past 5 years, Zevra Therapeutics' median EBT Margin value was 103.37% (recorded in 2021), while the average stood at 242.25%.
- In the last 5 years, Zevra Therapeutics' EBT Margin crashed by -19561400bps in 2022 and then skyrocketed by 18731300bps in 2023.
- Zevra Therapeutics' EBT Margin (Quarter) stood at 103.37% in 2021, then soared by 410bps to 319.93% in 2022, then plummeted by -148bps to 153.96% in 2023, then decreased by -10bps to 169.56% in 2024, then soared by 98bps to 3.74% in 2025.
- Its EBT Margin stands at 3.74% for Q3 2025, versus 296.93% for Q2 2025 and 9.4% for Q1 2025.